Articles producció científica> Medicina i Cirurgia

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

  • Datos identificativos

    Identificador: imarina:9216835
    Autores:
    Averna, MaurizioBanach, MaciejBruckert, EricDrexel, HeinzFarnier, MichelGaita, DanMagni, PaoloMaerz, WinfriedMasana, LuisMello e Silva, AlbertoReiner, ZeljkoRos, EmilioVrablik, MichalZambon, AlbertoZamorano, Jose L.Stock, Jane K.Tokgozoglu, Lale S.Catapano, Alberico L.
    Resumen:
    Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients. Methods: Evidence-based review. Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. Conclusions: This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
  • Otros:

    Autor según el artículo: Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; Maerz, Winfried; Masana, Luis; Mello e Silva, Alberto; Reiner, Zeljko; Ros, Emilio; Vrablik, Michal; Zambon, Alberto; Zamorano, Jose L.; Stock, Jane K.; Tokgozoglu, Lale S.; Catapano, Alberico L.;
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Masana Marín, Luis
    Palabras clave: Triglycerides Triacylglycerol Statin (protein) Risk reduction Risk benefit analysis Reduction (chemistry) Recurrent disease Proteinase inhibitor Proprotein convertase 9 Priority journal Practice guideline Pcsk9 protein, human Pcsk9 inhibitor evolocumab Of-function mutations Nutraceutical Note Non insulin dependent diabetes mellitus Monoclonal antibody Medical society Male Low density lipoprotein cholesterol level Low density lipoprotein cholesterol Lipid storage Lipid goals Ldl-c Ldl cholesterol Inflammation Inclisiran Icosapentaenoic acid ethyl ester Hypocholesterolemic agent Hypertriglyceridemia Hydroxymethylglutaryl-coa reductase inhibitors Hydroxymethylglutaryl coenzyme a reductase inhibitor Humans Human High-risk High risk patient High density lipoprotein cholesterol level High density lipoprotein cholesterol Heterozygous familial hypercholesterolemia Health care quality Goal attainment Fibric acid derivative Fenofibrate therapy Fenofibrate Female Familial hypercholesterolemia Ezetimibe Evidence based practice Eas dyslipidaemia guidelines Drug efficacy Dietary portfolio Diabetes mellitus, type 2 Density-lipoprotein cholesterol Coronary artery atherosclerosis Combination treatment Combination drug therapy Clinical trial (topic) Cholesterol, ldl Cardiovascular risk Cardiovascular effect Atherosclerosis Atherogenic index Anticholesteremic agents Adult Acute-coronary-syndrome Acid 2019 esc/eas dyslipidaemia guidelines 2019 esc
    Resumen: Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients. Methods: Evidence-based review. Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. Conclusions: This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
    Áreas temáticas: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: luis.masana@urv.cat
    Identificador del autor: 0000-0002-0789-4954
    Fecha de alta del registro: 2024-07-27
    Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
    Enlace a la fuente original: https://www.atherosclerosis-journal.com/article/S0021-9150(21)00162-3/fulltext
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Atherosclerosis. 325 99-109
    Referencia de l'ítem segons les normes APA: Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; Maerz, Winfried; Masana, Luis; Mello e Sil (2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 325(), 99-109. DOI: 10.1016/j.atherosclerosis.2021.03.039
    DOI del artículo: 10.1016/j.atherosclerosis.2021.03.039
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2021
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine,Peripheral Vascular Disease
    Triglycerides
    Triacylglycerol
    Statin (protein)
    Risk reduction
    Risk benefit analysis
    Reduction (chemistry)
    Recurrent disease
    Proteinase inhibitor
    Proprotein convertase 9
    Priority journal
    Practice guideline
    Pcsk9 protein, human
    Pcsk9 inhibitor evolocumab
    Of-function mutations
    Nutraceutical
    Note
    Non insulin dependent diabetes mellitus
    Monoclonal antibody
    Medical society
    Male
    Low density lipoprotein cholesterol level
    Low density lipoprotein cholesterol
    Lipid storage
    Lipid goals
    Ldl-c
    Ldl cholesterol
    Inflammation
    Inclisiran
    Icosapentaenoic acid ethyl ester
    Hypocholesterolemic agent
    Hypertriglyceridemia
    Hydroxymethylglutaryl-coa reductase inhibitors
    Hydroxymethylglutaryl coenzyme a reductase inhibitor
    Humans
    Human
    High-risk
    High risk patient
    High density lipoprotein cholesterol level
    High density lipoprotein cholesterol
    Heterozygous familial hypercholesterolemia
    Health care quality
    Goal attainment
    Fibric acid derivative
    Fenofibrate therapy
    Fenofibrate
    Female
    Familial hypercholesterolemia
    Ezetimibe
    Evidence based practice
    Eas dyslipidaemia guidelines
    Drug efficacy
    Dietary portfolio
    Diabetes mellitus, type 2
    Density-lipoprotein cholesterol
    Coronary artery atherosclerosis
    Combination treatment
    Combination drug therapy
    Clinical trial (topic)
    Cholesterol, ldl
    Cardiovascular risk
    Cardiovascular effect
    Atherosclerosis
    Atherogenic index
    Anticholesteremic agents
    Adult
    Acute-coronary-syndrome
    Acid
    2019 esc/eas dyslipidaemia guidelines
    2019 esc
    Saúde coletiva
    Psicología
    Peripheral vascular disease
    Odontología
    Nutrição
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Farmacia
    Engenharias ii
    Enfermagem
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciênci
  • Documentos:

  • Cerca a google

    Search to google scholar